Zevra Therapeutics (ZVRA) Operating Income: 2014-2025
Historic Operating Income for Zevra Therapeutics (ZVRA) over the last 11 years, with Sep 2025 value amounting to $4.1 million.
- Zevra Therapeutics' Operating Income rose 115.17% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$87.7 million, marking a year-over-year decrease of 1.07%. This contributed to the annual value of -$87.0 million for FY2024, which is 75.40% down from last year.
- Zevra Therapeutics' Operating Income amounted to $4.1 million in Q3 2025, which was up 105.83% from -$71.0 million recorded in Q2 2025.
- In the past 5 years, Zevra Therapeutics' Operating Income registered a high of $7.0 million during Q1 2021, and its lowest value of -$71.0 million during Q2 2025.
- Its 3-year average for Operating Income is -$19.0 million, with a median of -$15.4 million in 2023.
- Its Operating Income has fluctuated over the past 5 years, first spiked by 284.37% in 2021, then crashed by 590.21% in 2023.
- Quarterly analysis of 5 years shows Zevra Therapeutics' Operating Income stood at -$2.8 million in 2021, then slumped by 221.67% to -$9.1 million in 2022, then plummeted by 65.80% to -$15.2 million in 2023, then declined by 1.71% to -$15.4 million in 2024, then surged by 115.17% to $4.1 million in 2025.
- Its Operating Income stands at $4.1 million for Q3 2025, versus -$71.0 million for Q2 2025 and -$5.4 million for Q1 2025.